Topic: How To Invest

Pat, I would like your advice on this stock: Oncothyreon Inc. Regards.

Article Excerpt

Oncothyreon Inc., $5.79, symbol ONY on Toronto (Shares outstanding: 25.7 million; Market cap: $148.5 million) changed its name from Biomira at the end of 2007. Oncothyreon continues to lose money. It also has negative cash flow. As well, it’s still a development company, so it has no revenue. Oncothyreon holds cash of $22.7 million. It is using this up at a rate of around $12 million a year, so it shouldn’t face any pressure to raise more cash until at least the end of 2010. Currently, the company’s main development drug is Stimuvax, a cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen that is shared by many common cancers. MUC1 is over-expressed on many cancers, such as lung cancer, breast cancer, prostate cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body’s immune system to identify and destroy cancer cells that express MUC1. The drug is now in…